The selection of postoperative adjuvant treatment follows the strategy of “high-risk side guidance, combined coverage, and dynamic adjustment.” Per NCCN guidelines [12], the patient's right-sided tumor is high-risk (high proliferation index, multiple lymph node metastases) and HER2-positive, requiring intensive chemotherapy combined with trastuzumab-targeted therapy. This evidence concerns the gene ERBB2 and neoplasm.